Pooja Gokhale, Joshua Caballero, Niying Li, Lorenzo A. Villa Zapata. "Cost-effectiveness of amivantamab plus lazertinib versus osimertinib plus chemotherapy for first-line treatment of
                    <i>EGFR</i>
                    ‐mutated advanced non–small cell lung cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.8621